Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 9(7): e101199, 2014.
Article in English | MEDLINE | ID: mdl-25047083

ABSTRACT

Grey matter (GM) damage is a clinically relevant feature of multiple sclerosis (MS) that has been previously assessed with diffusion tensor imaging (DTI). Fractional anisotropy (FA) of the basal ganglia and thalamus might be increased in MS patients, and correlates with disability scores. Despite the established role of the striatum and thalamus in motor control, mood and cognition, the impact of DTI changes within these structures on motor and neuropsychological performance has not yet been specifically addressed in MS. We investigated DTI metrics of deep GM nuclei and their potential association with mobility and neuropsychological function. DTI metrics from 3T MRI were assessed in the caudate, putamen, and thalamus of 30 MS patients and 10 controls. Sixteen of the patients underwent neuropsychological testing. FA of the caudate and putamen was higher in MS patients compared to controls. Caudate FA correlated with Expanded Disability Status Scale score, Ambulation Index, and severity of depressive symptomatology. Putamen and thalamus FA correlated with deficits in memory tests. In contrast, cerebral white matter (WM) lesion burden showed no significant correlation with any of the disability, mobility and psychometric parameters. Our findings support evidence of FA changes in the basal ganglia in MS patients, as well as deep GM involvement in disabling features of MS, including mobility and cognitive impairment. Deep GM FA appears to be a more sensitive correlate of disability than WM lesion burden.


Subject(s)
Corpus Striatum/pathology , Gray Matter/pathology , Multiple Sclerosis/pathology , Adult , Brain/pathology , Diffusion Tensor Imaging , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuropsychological Tests
2.
Oncologist ; 19(6): 602-7, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24760710

ABSTRACT

Mutations in the IDH1 and IDH2 (isocitrate dehydrogenase) genes have been discovered across a range of solid-organ and hematologic malignancies, including acute myeloid leukemia, glioma, chondrosarcoma, and cholangiocarcinoma. An intriguing aspect of IDH-mutant tumors is the aberrant production and accumulation of the oncometabolite 2-hydroxyglutarate (2-HG), which may play a pivotal oncogenic role in these malignancies. We describe the first reported case of an IDH1 p.R132L mutation in a patient with hormone receptor-positive (HR+) breast adenocarcinoma. This patient was initially treated for locally advanced disease, but then suffered a relapse and metastasis, at which point an IDH1-R132 mutation was discovered in an affected lymph node. The mutation was subsequently found in the primary tumor tissue and all metastatic sites, but not in an uninvolved lymph node. In addition, the patient's serum and urine displayed marked elevations in the concentration of 2-HG, significantly higher than that measured in six other patients with metastatic HR+ breast carcinoma whose tumors were found to harbor wild-type IDH1. In summary, IDH1 mutations may impact a rare subgroup of patients with breast adenocarcinoma. This may suggest future avenues for disease monitoring through noninvasive measurement of 2-HG, as well as for the development and study of targeted therapies against the aberrant IDH1 enzyme.


Subject(s)
Adenocarcinoma/genetics , Breast Neoplasms/genetics , Isocitrate Dehydrogenase/genetics , Neoplasms, Hormone-Dependent/genetics , Adenocarcinoma/blood , Adenocarcinoma/pathology , Adenocarcinoma/urine , Breast Neoplasms/blood , Breast Neoplasms/pathology , Breast Neoplasms/urine , Female , Glutarates/blood , Glutarates/urine , Humans , Middle Aged , Mutation , Neoplasms, Hormone-Dependent/blood , Neoplasms, Hormone-Dependent/pathology , Neoplasms, Hormone-Dependent/urine
3.
Blood ; 120(23): 4649-52, 2012 Nov 29.
Article in English | MEDLINE | ID: mdl-23074281

ABSTRACT

Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recently described in acute myeloid leukemia (AML). Serum and myeloblast samples from patients with IDH-mutant AML contain high levels of the metabolite 2-hydroxyglutarate (2-HG), a product of the altered IDH protein. In this prospective study, we sought to determine whether 2-HG can potentially serve as a noninvasive biomarker of disease burden through serial measurements in patients receiving conventional therapy for newly diagnosed AML. Our data demonstrate that serum, urine, marrow aspirate, and myeloblast 2-HG levels are significantly higher in IDH-mutant patients, with a correlation between baseline serum and urine 2-HG levels. Serum and urine 2-HG, along with IDH1/2-mutant allele burden in marrow, decreased with response to treatment. 2-HG decrease was more rapid with induction chemotherapy compared with DNA-methyltransferase inhibitor therapy. Our data suggest that serum or urine 2-HG may serve as noninvasive biomarkers of disease activity for IDH-mutant AML.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Glutarates/metabolism , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/metabolism , Acute Disease , Aged , Azacitidine/administration & dosage , Azacitidine/analogs & derivatives , Cytarabine/administration & dosage , DNA Mutational Analysis , Decitabine , Female , Glutarates/blood , Glutarates/urine , Granulocyte Precursor Cells/metabolism , Humans , Idarubicin/administration & dosage , Isocitrate Dehydrogenase/genetics , Isocitrate Dehydrogenase/metabolism , Leukemia, Myeloid/genetics , Male , Middle Aged , Mutation , Prospective Studies , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...